review article | Q7318358 |
meta-analysis | Q815382 |
scholarly article | Q13442814 |
P356 | DOI | 10.1002/14651858.CD006186.PUB2 |
P8608 | Fatcat ID | release_p4ye65etmfctxd3wmlmfyqlluy |
P3181 | OpenCitations bibliographic resource ID | 743195 |
P698 | PubMed publication ID | 17636831 |
P2093 | author name string | Robert Hart | |
Lesly A Pearce | |||
Maria I Aguilar | |||
P2860 | cites work | Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation | Q22305336 |
Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks | Q24244742 | ||
The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials | Q24799154 | ||
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial | Q26248603 | ||
Measuring inconsistency in meta-analyses | Q27860655 | ||
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation | Q28165271 | ||
Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? | Q28166299 | ||
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin | Q28171104 | ||
Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study | Q28171184 | ||
Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation | Q28175307 | ||
Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation--a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin | Q28194171 | ||
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial | Q28194227 | ||
Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis | Q28194233 | ||
Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal | Q28195525 | ||
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
Lessons from the Stroke Prevention in Atrial Fibrillation trials | Q28196151 | ||
Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study | Q29614197 | ||
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study | Q29614200 | ||
Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin | Q33671179 | ||
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators | Q33863941 | ||
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study | Q34225539 | ||
Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack | Q46686096 | ||
Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. | Q53352979 | ||
Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. | Q53360138 | ||
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. | Q54114563 | ||
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications | Q72566134 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | patient | Q181600 |
anticoagulant | Q215118 | ||
transient cerebral isolation | Q593958 | ||
atrial fibrillation | Q815819 | ||
anticoagulation | Q63279445 | ||
P304 | page(s) | CD006186 | |
P577 | publication date | 2007-07-18 | |
P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
P1476 | title | Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks |
Q27341873 | 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society |
Q38073833 | A pragmatic strategy for the review of clinical evidence |
Q37417509 | A systematic review of Cochrane anticoagulation reviews. |
Q37741927 | Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study |
Q24241777 | Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack |
Q24234617 | Antiplatelet agents and anticoagulants for hypertension |
Q58040934 | Antiplatelet therapy for preventing stroke in people with atrial fibrillation |
Q52657350 | Atrial Cardiopathy and the Risk of Ischemic Stroke in the CHS (Cardiovascular Health Study). |
Q28084658 | Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation |
Q38981275 | Atrial fibrillation and chronic kidney disease: struggling through thick and thin. |
Q30238631 | Cardioembolic Stroke |
Q36336822 | Comparison of hemostatic dressings for superficial wounds using a new spectrophotometric coagulation assay. |
Q37342387 | Current management of atrial fibrillation: an observational study in NHS primary care |
Q37247723 | Deficits in discharge documentation in patients transferred to rehabilitation facilities on anticoagulation: results of a systemwide evaluation. |
Q24200617 | Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation |
Q94337721 | Direct thrombin inhibitors and factor Xa inhibitors for atrial fibrillation |
Q37442492 | Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? |
Q38261199 | Dual antiplatelet therapy in the anticoagulated patient undergoing percutaneous coronary intervention risks, benefits, and unanswered questions |
Q45813085 | Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study |
Q42676674 | Effectiveness and patient safety of platelet aggregation inhibitors in the prevention of cardiovascular disease and ischemic stroke in older adults - a systematic review |
Q42676634 | Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults - a systematic review of reviews and the development of recommendations to reduce inappropriate pres |
Q37479988 | Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on all-cause mortality in patients with diabetes and atrial fibrillation - a cohort study from Sweden using propensity score analyses |
Q28081598 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis |
Q36069462 | Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. |
Q44486681 | Ethnicity and stroke risk in patients with atrial fibrillation |
Q91649347 | Evidence-Practice Gaps in Postdischarge Initiation With Oral Anticoagulants in Patients With Atrial Fibrillation |
Q38169038 | Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association |
Q35900767 | Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study |
Q92994476 | Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D |
Q37701367 | Imaging of contrast medium extravasation in anticoagulation-associated intracerebral hemorrhage with dual-energy computed tomography |
Q33949432 | Impact of prescribed medications on patient safety in older people |
Q37725772 | Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts |
Q47291952 | Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore |
Q90194114 | Is Anticoagulation Necessary for Severely Disabled Cardioembolic Stroke Survivors? |
Q34242062 | Is isolated aphasia associated with atrial fibrillation? A prospective study |
Q49643122 | Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? |
Q95724841 | Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment |
Q41065525 | Left Atrial and Left Atrial Appendage 4D Blood Flow Dynamics in Atrial Fibrillation |
Q33713422 | Management of Atrial Fibrillation: Translating Clinical Trial Data into Clinical Practice |
Q39556840 | Modelling the cost-effectiveness of pharmacist-managed anticoagulation service for older adults with atrial fibrillation in Singapore. |
Q24201386 | Multiple versus one or more antiplatelet agents for preventing early recurrence after ischaemic stroke or transient ischaemic attack |
Q42907047 | New Approaches to Stroke Prevention in Atrial Fibrillation |
Q35566692 | Optimal antithrombotic strategy in patients with atrial fibrillation after coronary stent implantation |
Q38176288 | Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation |
Q89891735 | Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation |
Q34712397 | Patterns of warfarin use in subgroups of patients with atrial fibrillation: a cross-sectional analysis of 430 general practices in the United Kingdom. |
Q33585665 | Percutaneous Left Atrial Appendage Exclusion Therapy: Who, Why and How? |
Q37425335 | Pharmacogenetics and stroke |
Q37108889 | Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care |
Q37382897 | Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation |
Q89092899 | Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk |
Q38651209 | Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial |
Q41159155 | Prolonged Cardiac Monitoring to Detect Atrial Fibrillation after Cryptogenic Stroke or Transient Ischemic Attack: A Meta-Analysis of Randomized Controlled Trials. |
Q37599572 | Recent time trends in incidence, outcome and premorbid treatment of atrial fibrillation-related stroke and other embolic vascular events: a population-based study |
Q37613761 | Reducing the risk of stroke in elderly patients with non-valvular atrial fibrillation: a practical guide for clinicians |
Q35877931 | Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation |
Q40333529 | Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study |
Q55090406 | Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. |
Q38086826 | Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact. |
Q28359631 | Stroke Prevention in Atrial Fibrillation: Focus on Latin America |
Q36418118 | Stroke prevention: managing modifiable risk factors |
Q41486453 | The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study |
Q36409803 | The role of contraindications in prescribing anticoagulants to patients with atrial fibrillation: a cross-sectional analysis of primary care data in the UK. |
Q47559889 | Treatment of Atrial Fibrillation in Patients with Dementia: A Cohort Study from the Swedish Dementia Registry |
Q36449900 | Trends in the management of atrial fibrillation: A neurologist's perspective |
Q28553496 | Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis |
Q55359342 | Updates on Prevention of Cardioembolic Strokes. |
Q89408614 | Variation in anticoagulation for atrial fibrillation between English clinical commissioning groups: an observational study |
Q53759438 | Venous Thromboembolism in Primary Nephrotic Syndrome - Is the Risk High Enough to Justify Prophylactic Anticoagulation? |
Q37478238 | Warfarin in vulnerable older adults with atrial fibrillation |
Q46989595 | Warfarin prevails for stroke prevention in atrial fibrillation--even in octogenarians |
Q40646597 | Warfarin treatment and risk of myocardial infarction - A cohort study of patients with atrial fibrillation treated in primary health care |
Q57302446 | Warfarin: The End or the End of One Size Fits All Therapy? |
Q49347395 | Warfarin: better the devil you know |